On October 7, XTALPI fell 6.56% in regular trading, trading at 7.7 HKD/share, with Turnover of 27.2468 million HKD.
The decline is driven by broad weakness across the innovative drug and AI-driven pharmaceutical sector. Peer stocks including Genscript Biotech dropped 14.41%, Insilico Medicine fell 9.19%, and WuXi Bio declined 3.28%, reflecting sector-wide risk-off sentiment. This reversal follows a prior session rally, when XTALPI gained over 5% after announcing that its hair-loss pipeline had entered IND-enabling stage and amid expectations of valuation repricing catalyzed by an industry conference. The stock's pullback in this environment aligns with concurrent sector-wide volatility and profit-taking pressure in the life sciences tools and services space.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)